Morgan Stanley Maintains Overweight on Immix Biopharma, Lowers Price Target to $19

Benzinga · 3d ago
Morgan Stanley analyst Judah Frommer maintains Immix Biopharma (NASDAQ:IMMX) with a Overweight and lowers the price target from $20 to $19.